Abbott Launches ILUMIEN IV Trial To Drive Home Case For OCT

 
• By Reed Miller

ILUMIEN IV is the largest-ever prospective randomized trial to compare an intravascular imaging modality, plus angiography, to angiography alone in coronary interventions, according to Abbott. The trial will enroll up to 3,650 patients with high-risk complex disease at 125 centers in North America, Europe and Asia to determine if OCT-guided stenting yields larger vessel diameters and improves clinical outcomes for patients compared to stent procedures guided by standard angiography.

Render illustration of Clinical Trial title on medical documents

ILUMIEN IV, the largest randomized trial of intracoronary optical coherence tomography (OCT) as a guide for coronary intervention, has kicked off with the enrollment of the first patient in Italy. Trial-sponsor Abbott Laboratories Inc. announced the milestone earlier this month.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D